The continuous and semi-continuous bioprocessing market

Published by @j783803

3/30/22, 4:50 AM

The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification

London

Roots Analysis has announced the addition of “Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030” report to its list of offerings.

Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages.

To order this 190+ page report, which features 60+ figures and 115+ tables, please visit this https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html

Key Market Insights

Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics

Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific.

Over 65% of the installed continuous upstream manufacturing capacity belongs to established players

More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers.

Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost

By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion.

By 2030, the opportunity within the continuous and semi-continuous bioprocessing market is likely to be over USD 500 million

Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html

Key Questions Answered

§ Who are the leading contract manufacturers with expertise in continuous and semi-continuous bioprocessing?

§ Who are the leading innovators / drug developers with expertise in continuous and semi-continuous bioprocessing?

§ In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?

§ What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?

§ What is the currently installed global capacity for continuous and semi-continuous bioprocessing?

§ How is the current and future market opportunity likely to be distributed across key market segments?

The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:

§ Type of Manufacturer

§ Innovator / Drug Developer

§ Contract Service Provider

§ Company Size

§ Large

§ Mid-sized

§ Small

§ Scale of Operation

§ Preclinical / Clinical

§ Commercial

§ Stage of Bioprocess

§ Upstream Bioprocessing

§ Downstream Bioprocessing

§ Geographical Regions

§ North America

§ Europe

§ Asia-Pacific

§ MENA

§ Latin America and Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:

§ Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)

§ Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)

§ Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)

The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

§ AGC Biologics

§ Biogen

§ Bristol-Myers Squibb

§ Enzene Biosciences

§ FUJIFLM Diosynth Biotechnologies

§ Merck KGaA

§ Novasep

§ Sanofi Genzyme

§ UCB Pharma

§ WuXi Biologics

For additional details, please visit

https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html or email [email protected]